Kinnate Biopharma Stock (NASDAQ:KNTE)
Previous Close
$2.66
52W Range
$1.04 - $7.18
50D Avg
$2.49
200D Avg
$2.25
Market Cap
$124.99M
Avg Vol (3M)
$367.16K
Beta
1.34
Div Yield
-
KNTE Company Profile
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
KNTE Performance
Peer Comparison
Ticker | Company |
---|---|
GRCL | Gracell Biotechnologies Inc. |
SLRN | Acelyrin, Inc. |
LRMR | Larimar Therapeutics, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
STOK | Stoke Therapeutics, Inc. |
IPSC | Century Therapeutics, Inc. |
ERAS | Erasca, Inc. |
GBIO | Generation Bio Co. |
SRZN | Surrozen, Inc. |
KRON | Kronos Bio, Inc. |
BOLT | Bolt Biotherapeutics, Inc. |
PASG | Passage Bio, Inc. |
KROS | Keros Therapeutics, Inc. |
CCCC | C4 Therapeutics, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
DSGN | Design Therapeutics, Inc. |
WINT | Windtree Therapeutics, Inc. |
KZR | Kezar Life Sciences, Inc. |
FIXX | Q32 Bio Inc. |
PALI | Palisade Bio, Inc. |